- Cyclo Therapeutics Inc CYTH has submitted its initial investigational new drug (IND) application with the FDA for a Phase 2 study of Trappsol Cyclo for early Alzheimer's Disease (AD).
- Related Link: Cyclo Therapeutics' Trappsol Shows Early Safety, Efficacy In Genetic Disorder.
- The Company says that biologic similarities demonstrated between Niemann-Pick Disease Type C and Alzheimer's Disease bolster rationale for studying Trappsol for early Alzheimer's Disease.
- Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta-cyclodextrin.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: CYTH shares are up 2.23% at $7.45 during the market session on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
